Posted inBiotechnology
Efficient Kiwi Detection: Optimized YOLO for Embedded Systems
In the rapidly evolving field of precision agriculture, the need for innovative solutions to improve crop management and yield optimization…
Posted inMedical Technology
Hologic breast cancer study bolsters use of mammogram AI
Hologic has put forward more data bolstering the use of its artificial intelligence programs for detecting breast cancer through mammography.…
Posted inBiotechnology
Big Pharma-backed Aktis plans IPO to fund radiopharma trials
Big Pharma-backed Aktis Oncology has announced plans to go public, in the latest encouraging sign for those betting on a…
Posted inBiotechnology
Silencing SlERF.F5 Enhances Stress Tolerance in Tomato
In the realm of agricultural sciences, enhancing crop resilience against environmental stresses is a paramount challenge facing researchers today. Among…
Posted inBiotechnology
Novo Holdings-backed Windward buys rights to Qyuns’ clinical-stage immunology bispecific in $700M deal
Having kicked off the year with a $200 million series A, Windward Bio is ending 2025 splashing out on another…
Posted inBiotechnology
First Fatal French Case: Bromazolam, 2-MMC Poly-Use
In a groundbreaking forensic investigation that underscores the growing menace of novel psychoactive substances (NPS), French researchers have reported the…
Posted inBiotechnology
Ipsen continues ADC push with $1B deal for Simcere’s preclinical LRRC15-targeting asset
Ipsen may be a recent entrant into the antibody-drug conjugate space, but the French biopharma is continuing to make up…
Posted inBiotechnology
Finite Element Analysis of Titanium Cage Tilt Effects
In the realm of spinal surgeries, the intricacies of biomechanical engineering play a pivotal role in ensuring optimum patient outcomes.…
Posted inBiotechnology
AstraZeneca flunks phase 3 lung cancer test in further setback to synthetic lethal mechanism
A phase 3 study of AstraZeneca’s ceralasertib has missed its primary endpoint, dealing another blow to efforts to use a synthetic…
Posted inBiotechnology
AstraZeneca fronts $100M for Jacobio’s clinical-stage pan-KRAS inhibitor
AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset…